Hoth Therapeutics, Inc. (HOTH)
NASDAQ: HOTH · Real-Time Price · USD
1.300
-0.120 (-8.45%)
At close: Jun 13, 2025, 4:00 PM
1.280
-0.020 (-1.54%)
After-hours: Jun 13, 2025, 7:58 PM EDT
Hoth Therapeutics Employees
As of December 31, 2024, Hoth Therapeutics had 3 total employees, including 2 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
3
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$3,172,536
Market Cap
17.17M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
HOTH News
- 2 days ago - Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases - PRNewsWire
- 3 days ago - Hoth Therapeutics Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities - PRNewsWire
- 9 days ago - Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities - PRNewsWire
- 4 weeks ago - Hoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense Therapy Targeting Rare and Aggressive KIT-Driven Cancers - PRNewsWire
- 2 months ago - Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform - PRNewsWire
- 2 months ago - Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial - PRNewsWire
- 2 months ago - Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ - PRNewsWire
- 2 months ago - Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels, within 20 hours - PRNewsWire